OMI - NYSE

Good day and thank you for standing by. Welcome to Owens & Minor’s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instruction]. I would now like to hand the conference over to your first speaker today to Alex Jost, Director of Investor Relations.

Thank you. Hello, everyone, and welcome to the Owens & Minor’s third quarter 2022 earnings call. Our comments on the call will be focused on the financial results for the third quarter of 2022, as well as our outlook for 2022, both which are included in today’s press release. The press release along with the supplemental slides are posted on the Investor Relations section of our website. Please note that during this call, we will make forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Please refer to our SEC filings for a full description of these risks and uncertainties, including the risk factors section of our Annual Report on Form 10-K and quarterly reports on Form 10-Q. In our discussion today, we will reference certain non-GAAP financial measures, and information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I’m joined by Ed Pesicka, President and Chief Executive Officer; and Alex Bruni, Executive Vice President and Chief Financial Officer and Andy Long, Executive Vice President and Chief Executive Officer of Products and Healthcare Services will be joining us for the Q&A session. With that, I’ll turn the call over to Ed. Ed?

Thank you. Good morning, everyone and thank you for joining us on the call today. I'd like to start this call by addressing the factors that were in line with our expectations as well as the unanticipated factors that drove the recent change in our outlook. While there were some new challenges combined with the continuation and acceleration of existing challenges, many key aspects of the third quarter occurred as expected. Starting with one, we continued gaining momentum in our Patient Direct segment, growing organically in the mid to high teens across all major categories. We also continue to see improvement in our ability to access equipment, which allowed us to meaningfully reduce our overall backlog of orders in our sleep product line. Two as planned, we successfully onboarded new acute care customers and our product and healthcare services segment with the investments made in Q3 and Q4 providing benefits in the future. Three, as a result of our investments in predictive analytics, AI and inventory optimization, we continue to improve our already market leading service levels. And four, as expected and discussed last quarter, procedural volumes in Q3 were soft and well below the 2019 pre-pandemic levels. Now let me discuss the unanticipated factors in Q3 that drove our recent change in our outlook. One, as the third quarter progressed, we saw more and more of our acute care customers delay reorders choosing to deplete their stockpiled items including our higher margin S&IP products. Simply put, our previous guide has been a factor [Technical Difficulty].

Ladies and gentlemen, please stand-by your conference will resume momentarily. Please continue to hold your conference call will resume momentarily.

Apologize about the connectivity issues but let me continue back to where I left off at. So now let me discuss the unanticipated factors in Q3 that drove the recent changes in our outlook. First, as the quarter progressed, we saw more and more of our acute care customers delay reorders choosing to deplete their stockpiled items including our higher margin S&IP products. Simply put our previous guidance not factored this in as an assumption. Second, from a macroeconomic standpoint, the Federal Reserve actions were more aggressive than expected. The U.S. dollar strengthened and fuel prices reverse course and began to increase towards the end of Q3. Three, as we ended the third quarter, we concluded that the execution and velocity of the actions we were taking in our product and healthcare services segment were insufficient to offset the future impact of macroeconomic headwinds as we successfully had done in the past. And finally, while we were beginning to see slight improvements in procedural volume, we did not see the extent of the ramp up of procedural volumes, we expect it at the end of the third quarter and into Q4. Accordingly, we have made changes to address these shortfalls and the good news here is that there are numerous short-term and long-term opportunities in this segment that will allow us to operate more efficiently and more cost effectively. Here are just a few of them. One, we will continue to leverage our industry leading service levels. This has helped retain existing customers and win new business with attractive customers. This is an important distinction since as we have said in Q1 and Q2 not every customer is going to make financial and operational sense for us. We remain focused on profitable growth. Two, we are refocused on expanding our portfolio of products, which provide longer term benefits. Three, we are implementing changes in the way we incentivize our sales team to drive proprietary product penetration and conversion along with supporting our key supplier partners. And finally going forward, we will more aggressively implement the Owens & Minor business system into this segment. Simply put, we must execute better and faster. Moving on to the Patient Direct segment, the effectiveness of our business system is readily apparent in our Patient Direct segment. We have experienced many of the same macroeconomic pressures on this side of the business as well but have been able to offset some of the same challenges. The difference is simply in the execution. In the third quarter, our Patient Direct segment achieved organic revenue growth in the mid to high teens across sleep, diabetes, urology, ostomy, and continence and wound care. On a pro forma basis, this segment grew at 11.4% year-over-year. Also, our ability to procure sleep equipment was better than expected, which enabled us to grow our census of sleep patients and meaningfully reduce our backlog of orders. This highly recurring revenue base will compound nicely as we head into 2023. With the backlog of sleep patients clearing and the patient census growing, we will see more sleep supply sold in the future. And this will benefit the bottom-line. Finally, from an integration and synergy perspective, we are ahead of our internal targets. Overall, the patient direct segment will continue to be a larger and larger portion of the total company earnings and cash flow. We believe that the attractiveness of this faster growing higher margin segment is overlooked by the market. And the near-term and long-term perspectives of this segment is very exciting. Before I turn the call over to Alex to take you through the quarterly financials and our recently revised outlooks, I want to emphasize a few points. First, our commitment to the hospital customer and our industry leading service is paying off in new wins. Again, we will remain selective in pursuing the share gains that are most impactful to the bottom-line. Next, the use of stockpiled items for current activities by our customers is temporary. And as these stockpiles are depleted, demand for our S&IP products should return to normal. Three, you will see a more rapid and fulsome deployment of the Owens & Minor business system in the product and healthcare services segment. Four, I believe there will be an even greater appreciation for the strength and steadiness of our Patient Direct business. More and more of our earnings and EBITDA will be coming from our Patient Direct segment, and I believe the recurring revenue nature and growth rates of the segment will become properly valued. And finally, I am confident that our core business fundamentals remain strong, and we have the correct strategy across both business segments. With that, I will turn the call over to Alex for discussion of our financial results. Alex?

Thank you, Ed and good morning, everyone. It's my pleasure to be with you today and I look forward to meeting many of you in the weeks and months ahead. Today I'll review our financial results and key drivers for our performance in the third quarter, and then discuss our revised expectations and assumptions related to the full year outlook. First, let me start with our third quarter results. Our revenue in the quarter was $2.5 billion virtually flat from the prior year, driven by the contribution of Apria and strong organic growth within the Patient Direct segment offset by lower revenues within the products and healthcare services sector. Gross margin of $513 million or 20.6% of revenue was up 740 basis points from prior year. Growth was driven by Patient Direct and reflected the contribution of Apria sales and sales mix within that segment. Year-over-year for Q3 foreign currency negatively impacted revenue by $12 million, gross margin by $6 million and adjusted operating income by $5 million. Distribution, selling and administrative expense was $445 million driven higher primarily from the addition of Apria expenses and ongoing inflationary pressures, partially offset by operating efficiencies, and productivity gains derived from the Owens & Minor business system. Interest expense was $40 million in the quarter, which was $28 million higher than prior year driven by the debt financing of the Apria acquisition in late March. As a reminder, floating rate debt represents approximately 1/3rd of our overall borrowings inclusive of our interest rate swaps. The GAAP effective tax rate this quarter was 36.2% compared to 12.6% in last year's third quarter. The change in rates resulted primarily from the mixture of income and losses in jurisdictions in which we operate, as well as the prior year's utilization of foreign tax benefits. Our GAAP net income for the quarter was $12 million or $0.16 a share. Adjusted net income for the quarter was $31 million or $0.41 a share. Third quarter adjusted EBITDA was $127 million, with a margin of 5.1% up 140 basis points versus the prior year. On a segment basis products and healthcare services third quarter revenue was $1.9 billion, versus approximately $2.3 billion last year. This change was driven by approximately $110 million of lower glove cost pass-through, as well as reduced hospital demand and customers reliance on existing stockpiles. Products and healthcare services adjusted operating income for the quarter was $24 million compared to $64 million last year. And this change was attributable to the factors just discussed, along with accelerating inflationary pressures. Turning to Patient Direct, this segment had an excellent quarter. Net revenue in the quarter was $594 million, an increase of 142% year-over-year, growing 11.4% on a pro forma basis was strong double-digit growth across key product categories, and aided by our better-than-expected ability to procure sleep equipment. Adjusted operating income for the quarter was $60 million, compared to last year's third quarter of $50 million. The synergies we are generating within our patient direct business are tracking ahead of expectations. And we continue to expect Apria to add over $900 million of revenue and over $180 million of adjusted EBITDA for its nine months of contribution in 2022. In the next few years, we continue to expect deal synergies to add incremental annual revenue of $80 million to $100 million, an incremental annual adjusted EBITDA in the range of $40 million to $50 million. Moving now to cashflow, the balance sheet and capital structure. This quarter, we generated $69 million of cash from operations. And on a year-to-day basis, we have generated $238 million. Free cash flow defined as adjusted EBITDA, less net capital expenditures, with $84 million in the quarter, it's just under $300 million through the first nine months of 2022. During the quarter, we further reduced net debt by $35 million and we were comfortably within all debt covenant requirements. Leverage reduction remains a top priority, and there is no change in our target net leverage ratio of two to three times. Now let's look at our current guidance. For the full year 2022, we expect net revenue to be in a range of $9.8 billion to $10 billion. Adjusted EBITDA in a range of $527 million to $537 million and adjusted EPS in a range of $2.50 to $2.60. As we look at the key drivers of this revised outlook versus the previous guidance, there are a few items to note. First, we have reduced our revenue assumption by $50 million at the midpoint. This decrease reflects our new assumptions on software Q4 procedural volumes, and factors in the recent trends and customer reordering. As we mentioned, over the quarter, we saw more of our acute care customers delay reorders, choosing instead to deplete their product stockpiles. Given this, we are expecting a much different sales mix in Q4 than we had previously projected. This is driving the majority of the $0.45 reduction in the midpoint of the adjusted EPS guidance for the year. Expected interest expense for the year is slightly reduced to a range of $128 million to $130 million due to ongoing debt management and continuing to lower average daily debt levels partially offset by higher interest rate assumptions. For a complete summarized list of modeling assumptions, please refer to the supplemental slides filed with the SEC on Form 8-K earlier today, which we've also posted to the investor relations section of our website. Looking farther ahead, we are in the midst of our normal budgeting cycle, which would put us in a position to discuss our outlook for 2023 in the first quarter. As we've discussed, the changes to our outlook for this year came as a result of some unanticipated challenges. And without question, we are very focused and have a renewed urgency to address these issues. There were also many positive takeaways from the quarter. We are very proud of our service quality and new wins and successful onboarding within the products and healthcare services segment. And we remain very excited about the performance and outlook for the patient direct segment. Thank you. At this point, I'll turn the call back over to the operator to begin Q&A. Operator?

Thank you, sir. [Operator Instructions] And I show our first question comes from the line of Kevin Caliendo from UBS. Please go ahead.

Hi, good morning, everybody. It's actually Andrea Alfonso in for Kevin. I guess if we could just get a little bit more granularity around, your expectations for the run rate of margin and products in 2023. And if I could just slip one in, would appreciate a little bit more color on your thoughts around sort of the sleep apnea backlog and how we should think about that manifesting of the numbers from next year. Thanks so much.

Sure. I'll start this is, Ed. I'll start with the second part of the question and Alex will talk a little bit about the projection going forward. I think the way to think about the sleep product is, we had a very strong quarter in sleep. We were able to basically get access to additional product, the team executed extremely well on it. And, frankly, we took our backlog down to back to almost close to where we sitting now today, closer to normal levels of what we'd anticipate. So while we had anticipated the depletion of that backlog to lead us into Q1 of next year, and early part of 2023, we actually were able to capture most of that business now, because of the additional capacity that we receive or additional volume we received. And frankly, incredible execution on the teams part to get those products out. So how does that manifest into the future? Yes, obviously, placing the equipment is one thing, it's now that that recurring revenue will start to occur in Q4 or late in Q4, because generally they get a 90-day supply with the initial deployment of the product. And then that recurring revenue will start to continue to flow throughout all of 2023 versus where we originally thought, we would fill those equipment orders into '23, and then start to gain that. So it's really been strong execution on the patient direct team, focus on partnering with sleep manufacturers getting the product out to get us ahead of the curve, and really get our back orders and backlog on that back down to what we would see as a normal rate where we sit today. And then, I will, Alex cover a little bit on the first part of the question on kind of standard run rates, and where we are in the process.

Thanks, Ed. Good morning, Andrea. So within PHS, the trends that we've seen here in Q3, we do expect to continue at least in the short-term through Q4. And I think that's reflected in our guidance. And as I mentioned, we are in the middle of our budget process and do expect to have greater visibility in the first quarter. The markets continue to be very dynamic. And we'll work through that over the next month or so.

Thanks very much.

Thank you. One moment for our next question. And I show a next question comes from the line of Daniel Grosslight from Citi. Please go ahead.

Hi, guys, thanks for taking the question. It seems like most of the pressures you're facing are macro in nature. But you mentioned that there are specific actions you didn't take quickly enough and you're going to begin implementing. I'm wondering if you could put just a bit of a finer point on what specifically you can do in the near-term given these macro pressures don't seem to be abating anytime soon. And how quickly that will manifest in more normalized margins for the products and solutions business?

Sure, I'll take that. So really, it's both a mix of macro as well as some of the industry specific that we're seeing. So I talked a little bit about the destocking, that's having a material impact on us here in Q3 and then extending into Q4 and that's really the fact that hospitals are under financial constraint. They have a tremendous amount of stock on hand of PPE which historically they haven't had. They are electing to utilize that versus restocking. So they're using their “safety stock” to bleed down inventory, which is having a material impact on us. I think on the macroeconomic side there are several different things that we're in the process of doing. Some of those things to offset the macro impact one is Route Optimization as fuel prices continue to go up, there's still tremendous opportunities for us to maximize and optimize our Route Optimization within the customers and that's going to take a period of time to work with our customers from a delivery standpoint. There's additional really embedding the Owens & Minor Business System within our product and healthcare services segment. There's the ability for us to continue to take cost out of that business aggressively by driving continuous improvement and I think the way to really look at it is compare and contrast the two segments. Many of the same macroeconomic pressures impact Patient Direct that impact our product and healthcare services segment. Our Patient Direct through the embedding of the Owens & Minor Business System have been able to quickly take cost out of that system to be more effective. That same implementation has to happen on the other side of our business on the product and healthcare services segment. The other thing, I would talk about to really continue to look at off-sizing some of the macroeconomic is looking at the labor force. One of the things we had anticipated coming into Q3 and going into Q4 was the stabilization of the labor. We didn't see that in Q3 and Q4. However, we actually believe as the economy continues to tighten, the labor force will create opportunities for us to have a better labor force and then keep our employees and teammates for a longer period of time and reduce that turnover. So that's another aspect of it, continuing to look at ways where we've identified of how do we reduce the turnover of our teammates and our distribution centers so that way, we can have well-trained teammates that are much more effective than new hires. So that's another aspect of how we're thinking about it.

Thanks. Appreciate the color. And if I could slip one more in here, you mentioned a lot of the margin pressure within products and solutions is due to product mix as well, the higher margin products just haven't come back as much as you expected. Given you had generally seeing higher margins within your proprietary products business, does this mean you're really seeing most of the pressure within proprietary products, rather than the core distribution segment?

I think that's the right way to think about it and really it comes down to this is, while we're winning customers, we're continuing to grow in our general distribution business, the one area we're seeing today primarily our Proprietary S&IP products, we're seeing less and less demand. We're not seeing utilization go down in the hospital of the product, we're actually seeing hospitals reduce their purchasing of those products because they have a stockpile and that's one of the things that's fundamentally changed is during COVID of the last few years many of our customers went out and bought product from us from other manufacturers and then directly anywhere they could find the product. They built those products up in a stockpile and now they're electing to actually utilize those products that are in their stockpile, deplete those down to a lower level and then that's when the recurring revenue will start to happen and increase again in our products business, specifically the PPE based products.

Thanks, appreciate the color.

Thank you. And I show our next question comes from the line of John Stansel from JPMorgan. Please go ahead.

Hi, this is John on for Lisa. Thanks for taking my question. I just want to dig in a little bit on the synergies that you're seeing, I think you called out kind of ahead of schedule but if I was hearing kind of the commentary correct about the same amount that $40 million to $50 million of EBITDA contribution. So I guess my question is, are you seeing a more than expected just synergies from your overall integration? And I guess, how should we think about that going forward?

Yes. The answer to that question is, absolutely we are. Again we -- I've watched the Patient Direct business come together at [Apria and Byram] [ph], I've watched them both collectively embrace and embed the Owens & Minor Business System. We've watched them continue to grow. If you think about the growth, right, I think Q2 pro forma growth rate was approximately 10% and Q3 pro forma growth rate is 11.4%. So just think about that, the ability to cross-sell, the ability to identify opportunities. I would say there's synergies on both sides and the fact that we've embraced the fact that Byram has learned from Apria and Apria has learned from Byram. Byram has effectively done some of the things that have made Apria successful and Apria has done many of the things that has made Byram successful. Again, you're seeing that in growth, again pro forma last quarter, this quarter was 10%, up to 11.4%, you're seeing that in operating income overall, I believe we went from 9.1% to 10%, adjusted operating income as percentage. So you're seeing margin expansion. And again, that is driven by cost elimination that has been driven by better operational effectiveness, that is driven by a top-line growth. And I think it's also important with the synergies, we're seeing growth not just in one category two categories, but virtually all major categories grew at double digits. So those are the quantitative examples that are validating the synergies and continuing to drive the adjusted operating income margin expansion as well as accelerated top-line growth.

Great, thank you.

Thank you. And I show our next question comes from the line of Charlotte Kolb from Bank of America. Please go ahead.

Hi, this is Charlotte on for Mike. Thanks for taking my question. Can you talk a little bit about the competitive environment and any impacts that you're seeing from a share perspective versus peers?

Yes, from a competitive environment, I mean all the businesses are different obviously, we've got a manufacturing business, we got a distribution business, we got a Patient Direct business. I would like to -- I believe that if I take those in the other order our product, our Patient Direct business continues to grow again I said at 11.4%, of pro forma and really in the high teens are double digits across the Board, I should say within all major categories. So I like to believe that in those markets we're playing, we are continuing to grow at or above market. I would say also within our medical distribution, we continue to see new meaningful wins come into our business. But I'll also qualify that as in the fact that we're continuing to look at the right wins and retaining the right business. We look at it as is there meaningful losses, and can we gain meaningful wins? And across the Board I would say we're gaining some very meaningful wins with the opportunities for those to continue to grow. We're also doing putting together programs with our medical distribution business that when we win customers -- a great example of that is one of the recent announcements we had in WVU. That's not just an opportunity to win, there it's to grow in the entire state with the footprint we're adding and then the geographic states around that. So that's where I say, there's great success on that. I would say in the PPE space, we’re in our proprietary products, I think the destocking isn't just affecting us, it's affecting many others in the market too that are in this space. And as we look at our contracts across our customer base, we continue to maintain those we continue to have expansions of new customers coming onto our PPE -- coming onto our contracts are PPE. So I think across the Board we're doing extremely well.

Great. Thank you.

Thank you. I'm showing no further questions in the queue. At this time, I'd like to turn the call back over to Mr. Pesicka for closing remarks.

Thank you. Well, first, I just want to thank everyone for joining us on the call today, but before I end the call, I want to reiterate a few key points that I want to make sure we all take away from today's conversation. First, at Owens & Minor, we are completely committed to our customers and continuing to provide leading industry or industry leading services. That service level we're providing continues to deliver on new wins for us and we're going to continue to focus and as I just stated in the previous question, the right growth going forward. Second really the stockpile issue, we've got customers that have a tremendous amount of product stockpile. We're seeing customers utilize that stockpile. I met with a customer most recently that had been burning through their stockpile and now was completely through it, met with other customers that validated it, yes, we're utilizing some of our stockpiles offset some of the financial woes. As that stockpile is depleted and it's not going to last forever, that demand for our product exists, it still exists, and they're using those products today. Next, you're going to see really an increased intensity around the Owens & Minor business system and our product and healthcare services segment. Finally, we've talked about this back in Q1, Q2 and in various open communications. You're going to continue to see a mix shift at Owens & Minor, where more and more of our earnings and EBITDA are going to come from the Patient Direct segments and I really believe as people understand that segment, it has tremendous recurring revenue nature as well as it has higher growth and it's a more profitable segment than our patient, our product and healthcare services segment and you're going to continue to see that mix shift as we go forward. And finally, over the long-term, I am completely confident that our core business fundamentals remain strong, and we have the correct strategies across both segments. So I want to thank everyone, and I look forward to sharing our progress when we report out our fourth quarter results in early 2023. Thank you.